This year's event in Boulder was a great success! Photos from the event and videos of the presentations will be available on the Boulder Peptide Society webpage soon.
Richard DiMarchi, Ph.D. the Standiford H. Cox Distinguished Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University has been named as the 2015 recipient of the Meienhofer Award for Excellence in Peptide Sciences. Read the announcement.
The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015. The Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development. BPS is pleased to offer a preview of this year's program.
Richard DiMarchi, Ph.D. the Standiford H. Cox Distinguished Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University has been named as the 2015 recipient of the Meienhofer Award for Excellence in Peptide Sciences. The award will be presented to Dr. DiMarchi on September 30, 2015 at the Boulder Peptide Symposium, which will take place from September 28 to October 1, 2015 in Boulder, Colorado, where Dr. DiMarchi will give a presentation of highlights from his prodigious record of research achievements.
Dr. DiMarchi's contributions in peptide & protein sciences consist of three decades of work in academia, the pharmaceutical industry and biotechnology companies. He is a co-founder of Ambrx, Inc., Marcadia Biotech, Assembly, Calibrium and MB2 Biotech. He has served as a scientific advisor to multiple pharmaceutical companies (Kai, Ferring, Lilly, Merck, and Roche), three venture funds; 5AM, TMP, Twilight and a former board member of BIO, Isis and Millenium-Bio. He is currently Chairman of the Peptide Therapeutics Foundation and external board member at Assembly Biosciences and On-Target Therapeutics.
Dr. DiMarchi earned his Ph.D. from Indiana University in 1979. He completed post-doctoral training at Rockefeller University under the mentorship of Noble Laureate Prof. Bruce Merrifield after which he began a twenty-two year career as a scientist and executive at Eli Lilly and Company. For more than two decades at Lilly Research Laboratories he provided leadership in biotechnology, endocrine research and product development, retiring as Group Vice President in 2003. The focus of much of Dr. DiMarchi’s research has been the chemical biology of endocrine hormones, and more specifically those pertaining to diabetes and obesity. He is readily recognized for discovery and development of rDNA derived Humalog® (LisPro-human insulin) and the advancement of mixed incretin agonists for treatment of the metabolic syndrome. As scientist and executive, Dr. DiMarchi also significantly contributed to the commercial development of Humulin®, Humatrope®, rGlucagon®, Evista®, and Forteo®. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization, an approach he has termed chemical-biotechnology. He is the author of nearly two hundred scientific publications and holds more than a hundred patents.
Dr. DiMarchi is the recipient of numerous awards including the 2005 AAPS Career Research Achievement Award in Biotechnology, the 2006 ACS Barnes Award for Leadership in Chemical Research Management, the 2006 ACS Esselen Award for Chemistry in the Service of Public Interest, the 2007 Carothers Award for Excellence in Polymer Sciences, the 2009 Watanabe Award for Life Sciences Research, the 2011 Merrifield Award for Career Contributions in Peptide Sciences, the 2012 Phillip Nelson Innovation Award, the 2014 Erwin Schrödinger-Preis, a 2014 inductee to the National Inventors Hall of Fame, a 2015 winner of the Patient Advocacy award of the philanthropic society Cures within Reach, a 2015 inductee to the National Association of Inventors.
More information on the Meienhofer Award, including a list of previous recipients, and the Boulder Peptide Symposium can be found online at www.boulderpeptide.org.
May 11, 2015 - Boulder, Colorado
The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015. Discounted early registration is available until May 31 on the BPS website at:
Boulder Peptide Symposium 2015 Registration
The Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development. BPS is pleased to offer a preview of this year's program.
Scientific Sessions: Chemistry and Analytics
Synthesis and bioactivity of glycopeptides and peptide-protein conjugates, Thomas Tolbert, Associate Professor, The University of Kansas
Macrocyclic Organo-Peptide Hybrids as Molecular Scaffolds for Targeting Protein-Protein Interactions, Rudy Fasan, Associate Professor, University of Rochester
Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel, Les Miranda, Director Research, Therapeutic Discovery, Amgen Inc.
Cell-penetrating peptides: current landscape & future applications, Francesca Milletti, Principal Scientist, Roche
Scientific Sessions: Peptides in the Clinic
Injecting Hope: Clinical Development of the NeuVax Vaccine, Elizabeth Mittendorf, Associate Professor, Deputy Chair Research, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
The Clinical Development of Peixganan for the Treatment of Diabetic Foot Infections, Warren Joseph, Consultant, Lower Extremity Infectious Diseasess, Roxborough Memorial Hospital, Philadelphia, PA
Clinical efficacy of a novel P-15 peptide in anterior cervical arthrodesis: A prospective, randomized, controlled, multicenter study, Jerome Connor, Vice President of Research and Development, Cerapedics Inc.
First in class anti-infectives from a novel cationic peptide platform, Deborah O'Neil, Chief Executive & Scientific Officer, NovaBiotics Ltd.
The Clinical Development of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Extensive-stage Small Cell Lung Cancer (SCLC) and Metastatic Renal Cell Carcinoma (mRCC), John R. Stille, Senior Clinical Research Advisor, Eli Lilly and Company
Scientific Sessions: Drug Delivery and Formulations
MICROCOR®: A novel platform transdermal technology for convenient and effective delivery of peptides, Bobby Singh, CTO, Corium International, Inc.
A Chemical Approach to Half-life Extension of Peptides and Proteins, Daniel Santi, President, ProLynx
ELP Biopolymers Significantly Enhance the Pharmacology of Therapeutic Peptides, Jim Ballance, VP Research & Scientific Affairs, PhaseBio Pharmaceuticals, Inc.
Development of a Topical Anti-inflammatory Cell Permeable Peptide for Uveitis, Bruce Littman, CEO, Portage Pharmaceuticals LTD
Peptide Showcase
M. Karen Newell-Rogers, Professor/Consultant, VG Life Sciences/Texas A&M Health Sciences Center
Robin Carmichael, President &COO, Helix BioMedix
Ken Cundy, Chief Scientific Officer, CohBar, Inc.
Michael Sekar, Sr. Director, Formulation Research, Durect Corporation
Andreas Rybka, Head of Chemistry, Nexigen GmbH
Nozer Mehta, Vice President, Biologics, MonoSol Rx
Pascal Deschatelets, Chief Operating Officer, Apellis Pharmaceuticals
Craig Beattie, Chief Scientific Officer, CDG Therapeutics
Jamal Temsamani, Director of Drug Development, Vect-Horus
Fa Liu, Director of Chemistry, Calibrium, LLC
If you wish to be considered for a presentation, please apply at the link:
http://www.boulderpeptide.org/apply-to-present
The 9th Annual meeting will take place at the beautiful St. Julien Hotel and Spa, which has been the venue for this meeting since it’s inception. Boulder Peptide Society is a nonprofit 501(c)(3) organization. More information about the mission of the society and the details of the meeting can be found on the website at www.boulderpeptide.org.
March 10, 2015 - Boulder, Colorado
The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015. The Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development. BPS is pleased to offer a preview of this year's program.
Synthesis and bioactivity of glycopeptides and peptide-protein conjugates, Thomas Tolbert, Associate Professor, The University of Kansas
Macrocyclic Organo-Peptide Hybrids as Molecular Scaffolds for Targeting Protein-Protein Interactions, Rudy Fasan, Associate Professor, University of RochesterS
Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel, Les Miranda, Director Research, Therapeutic Discovery, Amgen Inc.
Cell-penetrating peptides: current landscape & future applications, Francesca Milletti, Principal Scientist, Roche
Injecting Hope: Clinical Development of the NeuVax Vaccine, Elizabeth Mittendorf, Associate Professor, Deputy Chair Research, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
The Clinical Development of Peixganan for the Treatment of Diabetic Foot Infections, Warren Joseph, Consultant, Lower Extremity Infectious Diseasess, Roxborough Memorial Hospital, Philadelphia, PA
Clinical efficacy of a novel P-15 peptide in anterior cervical arthrodesis: A prospective, randomized, controlled, multicenter study, Jerome Connor, Vice President of Research and Development, Cerapedics Inc.
First in class anti-infectives from a novel cationic peptide platform, Deborah O'Neil, Chief Executive & Scientific Officer, NovaBiotics Ltd.
The Clinical Development of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Extensive-stage Small Cell Lung Cancer (SCLC) and Metastatic Renal Cell Carcinoma (mRCC), John R. Stille, Senior Clinical Research Advisor, Eli Lilly and Company
MICROCOR®: A novel platform transdermal technology for convenient and effective delivery of peptides, Bobby Singh, CTO, Corium International, Inc.
A Chemical Approach to Half-life Extension of Peptides and Proteins, Daniel Santi, President, ProLynx
ELP Biopolymers Significantly Enhance the Pharmacology of Therapeutic Peptides, Jim Ballance, VP Research & Scientific Affairs, PhaseBio Pharmaceuticals, Inc.
Development of a Topical Anti-inflammatory Cell Permeable Peptide for Uveitis, Bruce Littman, CEO, Portage Pharmaceuticals LTD
M. Karen Newell-Rogers, Professor/Consultant, VG Life Sciences/Texas A&M Health Sciences Center
Robin Carmichael, President &COO, Helix BioMedix
Ken Cundy, Chief Scientific Officer, CohBar, Inc.
Michael Sekar, Sr. Director, Formulation Research, Durect Corporation
Andreas Rybka, Head of Chemistry, Nexigen GmbH
Nozer Mehta, Vice President, Biologics, MonoSol Rx
Pascal Deschatelets, Chief Operating Officer, Apellis Pharmaceuticals
Craig Beattie, Chief Scientific Officer, CDG Therapeutics
Jamal Temsamani, Director of Drug Development, Vect-Horus
Fa Liu, Director of Chemistry, Calibrium, LLC
If you wish to be considered for a presentation, please apply at the link:
http://www.boulderpeptide.org/apply-to-present
The 9th Annual meeting will take place at the beautiful St. Julien Hotel and Spa, which has been the venue for this meeting since it’s inception. Boulder Peptide Society is a nonprofit 501(c)(3) organization. Moreinformation about the mission of the society and the details of the meeting can be found on the website at www.boulderpeptide.org.
The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015.
In preparation, the Society Board of Directors has assembled an esteemed Scientific Advisory Board with significant industry and academic experience in discovery and development of peptide therapeutics. The SAB is responsible for identifying, soliciting, and reviewing speakers for the scientific sessions, business showcase, Meienhofer and Young Investigator Awards, posters, and for editing the newsletter. We thank the 2015 SAB members below for volunteering their time to make the meeting a success.
If you wish to be considered for a presentation, please apply at the link:
http://www.boulderpeptide.org/apply-to-present
The 9th Annual meeting will take place at the beautiful St. Julien Hotel and Spa, which has been the venue for this meeting since it’s inception. Boulder Peptide Society is a nonprofit 501(c)(3) organization. Moreinformation about the mission of the society and the details of the meeting can be found on the website at www.boulderpeptide.org.
Boulder, CO, January 20, 2015 -- The Boulder Peptide Society will host its 9th Annual meeting in late September 2015 in Boulder, Colorado. In preparation, the society has issued a call for abstracts for the three core scientific sessions of the meeting:
Scientific Session 1: Peptides in the Clinic
Oral presentations on peptide therapeutics in clinical development with an emphasis on human clinical data in Phase II or beyond.
Scientific Session 2: Drug Delivery
Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies
Scientific Session 3: Chemistry and Analytics
Novel peptide synthesis, conjugation, and side-chain modification chemistries along with advanced analytical techniques applicable to peptide therapeutics will be presented.
Apply now on our website.
The 2015 Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development.
The Boulder Peptide Symposium is a nonprofit organization. More information about the mission and the annual meeting can be found on the website at www.boulderpeptide.org.
Rapidly Adaptable Antibacterial Agents for Treating Multidrug Resistant Infections,
Chief Scientific Officer, Circle Pharma
Rapidly Adaptable Antibacterial Agents for Treating Multidrug Resistant Infections,
Techulon Inc
Discovery of functional ligands and materials from genetically-encoded libraries of chemically-modified peptides,
University of Alberta
Targeting protein-protein interactions with engineered cyclotides,
University of Southern California
Controlling Autoimmune Diseases Using Bifunctional Peptide Inhibitors (BPI),
University of Kansas
The Discovery and Preclinical Development of MTI-101, a Cyclic Beta-Hairpin Peptide with in Vivo Activity Against Myeloma and Lung Cancer.,
Executive Vice President, Modulation Therapeutics Incorporated
Intranasal Delivery of Peptide Therapeutics: Challenges and Strategies,
Scientist, MedImmune
Macrocyclic Peptide Drug Discovery: Protein-Protein Interaction Target Space,
Distinguished Scientist & Head, Peptide Drug Discovery and Innovative Technologies, Merck Research Laboratories
Peptide macrocyclization enabled by cysteine arylation,
Assistant Professor of Chemistry, Massachusetts Institute of Technology
Antimicrobial Peptides: Innate Defense Against Ocular Surface Pathogens and Potential Therapeutic Use,
University of Houston
Boulder, Colorado – August 11, 2014
Jean Rivier, Ph.D. the Dr. Frederik Paulsen Chair in Neurosciences and professor in The Clayton Foundation Laboratories for Peptide Biology at the Salk Institute for Biological Studies has been named as the 2014 recipient of the Meienhofer Award for Excellence in the Peptide Sciences. The award will be presented to Dr. Rivier on Tuesday the 23rd of September at the Boulder Peptide Symposium, where Dr. Rivier will give a presentation of highlights from his prodigious record of research achievements.
Dr. Rivier earned his Ph.D. from the University of Lausanne, Switzerland in 1969. He then came to the Salk Institute in 1970 as a research associate by way of a post doc at Rice University. Dr. Rivier was appointed Professor, Clayton Foundation Laboratories for Peptide Biology at Salk in 1989, a position, among others, that he holds to this day.
Dr. Rivier is the author of over 650-refereed papers, and holds more than 125 patents. The focus of much of Dr. Rivier’s work has been the biology and chemistry of hypothalamic hormones. His life’s work on the peptides and analogs of Corticotropin Releasing Hormone, Growth Hormone Releasing Hormone, Somatostatin, and Gonoadotropin Releasing hormone have provided the causative motive force behind the discovery of hormone derived peptide drugs in the marketplace which have grossed more than $1Billion.
Dr. Rivier has held positions on the Scientific Advisory Boards for numerous biotechnology companies including Alanex, Neurocrine Biosciences, Peptor, Balance Pharmaceuticals, and Cognetix.
A leader in the peptide community, Dr. Rivier co-founded the American Peptide Society. and was elected President in 1994-5. In 1990, he was recognized as the recipient of the Vincent du Vigneaud Award and in 1994, he received the Sidney H. Ingbar Distinguished Service Award of the Endocrine Society.
More information on the Meienhofer Award, including a list of previous recipients, and the Boulder Peptide Symposium can be found online at www.boulderpeptide.org.